Literature DB >> 22419662

The effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive families.

Chin-Fu Hsiao1, Wayne W H Sheu, Yi-Jen Hung, Ming-Wei Lin, David Curb, Koustubh Ranadex, Thomas Quertermous, Yue-Ming Chen, Ida Yi-Der Chen, Kwan-Dun Wu.   

Abstract

INTRODUCTION: The hereditability of insulin resistance has been demonstrated in both familial and twin studies. The effects of renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance remain inconclusive.
METHODS: This is a sibling-based association study. Polymorphisms of renin-angiotensin-aldosterone system genes were examined in 1113 hypertension and 676 normotension siblings from Chinese and Japanese hypertensive families. The generalized estimation equations method was used to compare the differences in metabolic variables between hypertension and normotensive siblings.
RESULTS: For the G-6A polymorphism of AGT, GG siblings had lower 2-h insulin than siblings carrying the A allele (p=0.006). Siblings with different variants of the angiotensin II type 1 receptor A1166C had no difference in metabolic variables. Siblings carrying the D allele of the angiotensin converting enzyme gene had higher levels of fasting glucose, fasting insulin, area under the curve of insulin levels and the homeostasis model assessment of insulin resistance than II siblings (all p<0.05). Lower levels of fasting glucose and 2-h glucose were observed in siblings with the T allele than their CC homozygotes for the C-344T polymorphism of CYP11B2 (p<0.05). Siblings carrying three high-risk genotypes of the angiotensin converting enzyme, angiotensinogen and CYP11B2 had higher fasting glucose level than siblings carrying no high-risk genotypes (p=0.011).
CONCLUSION: Our comprehensive analysis of renin-angiotensin-aldosterone system gene polymorphisms demonstrates that the angiotensin converting enzyme and CYP11B2 gene polymorphisms are associated with insulin resistance in hypertensive families.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419662      PMCID: PMC4111239          DOI: 10.1177/1470320312438790

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  49 in total

1.  An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

Authors:  Muneya Fujimoto; Hiroaki Masuzaki; Tomohiro Tanaka; Shintaro Yasue; Tsutomu Tomita; Kayoko Okazawa; Junji Fujikura; Hideki Chusho; Ken Ebihara; Tatsuya Hayashi; Kiminori Hosoda; Kazuwa Nakao
Journal:  FEBS Lett       Date:  2004-10-22       Impact factor: 4.124

2.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

3.  Kinetics of the human renin and human substrate reaction.

Authors:  A B Gould; D Green
Journal:  Cardiovasc Res       Date:  1971-01       Impact factor: 10.787

4.  Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx.

Authors:  L M DeWitt; J W Putney
Journal:  FEBS Lett       Date:  1983-08-22       Impact factor: 4.124

5.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

6.  Regulation of gluconeogenesis by norepinephrine, vasopressin, and angiotensin II: a comparative study in the absence and presence of extracellular Ca2+1.

Authors:  N M Kneer; H A Lardy
Journal:  Arch Biochem Biophys       Date:  1983-08       Impact factor: 4.013

7.  Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects.

Authors:  Fabrice Bonnet; Sheila Patel; Martine Laville; Beverley Balkau; Angela Favuzzi; Lucilla D Monti; Nebojsa Lalic; Mark Walker
Journal:  Diabetes Care       Date:  2008-01-30       Impact factor: 19.112

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study.

Authors:  Kwan-Dun Wu; Chin-Fu Hsiao; Low-Tone Ho; Wayne Huey-Herng Sheu; Dee Pei; Lee-Ming Chuang; David Curb; Yii-Der Ida Chen; Hui-Ju Tsai; Victor J Dzau; David Cox; Tong-Yuan Tai
Journal:  Hypertens Res       Date:  2002-07       Impact factor: 3.872

10.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.

Authors:  M Modan; H Halkin; S Almog; A Lusky; A Eshkol; M Shefi; A Shitrit; Z Fuchs
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

View more
  4 in total

Review 1.  DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.

Authors:  Chayakrit Krittanawong; Andrew Xanthopoulos; Takeshi Kitai; Natalia Branis; HongJu Zhang; Marrick Kukin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 2.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

Review 3.  Obesity genetics and cardiometabolic health: Potential for risk prediction.

Authors:  Dharambir K Sanghera; Cynthia Bejar; Sonali Sharma; Rajeev Gupta; Piers R Blackett
Journal:  Diabetes Obes Metab       Date:  2019-03-20       Impact factor: 6.577

4.  Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism Is Not Responsible for Antihypertensive Therapy Induced New Onset of Type 2 Diabetes in Essential Hypertension.

Authors:  Vikas Jhawat; Sumeet Gupta; Bimal K Agarwal; Partha Roy; Vipin Saini
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-01-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.